Clinical trial

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCompletedPhase 1Started Nov 1, 200726 enrolledUnited StatesNCT00566098

Abstract

RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.

Keywords

stage II multiple myelomastage III multiple myelomaMultiple Myeloma and Plasma Cell Neoplasm

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.